drugset
drugset / Trial / NCT00802555

Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)

NCT00802555 ↗

Phase 1 Completed 21 enrolled ArQule, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Multi-center, single-arm Phase 1b study designed to evaluate safety and tolerability of ARQ 197 in cirrhotic patients with HCC.

Timeline

Start
2009-01
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tivantinib Small molecule 360 mg —

Indications

cirrhosis of liver hepatocellular carcinoma